US36315X1019
US36315X1019
Lakefront Biotherapeutics
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.95B EUR | 1.97B EUR | 1.98B EUR | 2.15B EUR |
Enterprise Value | 36.52B EUR | 1.84B EUR | 1.92B EUR | 2.07B EUR |
Valuation Multiples | ||||
Trailing P/E | 2.8x | 3.3x | 4.04x | 4.54x |
Forward P/E | -25.01x | -- | -- | -- |
Price to Sales | 1.97x | 1.99x | 1.89x | 2.08x |
Price to Book | 10.68x | 0.6x | 0.61x | 0.67x |
EV/Revenue | 36.86x | 1.86x | 1.84x | 2x |
EV/EBITDA | 64.19x | 2.78x | 3.36x | 2.97x |
Price to FCF (P/FCF) | 14.09x | -- | -- | -- |
EV/FCF | 264.22x | -- | -- | -- |
FCF Yield | 7.1% | -11.76% | -15.7% | -10.56% |